FCOM 2025: Oral Mucosal Immunotherapy for Allergic Rhinitis

Oral mucosal immunotherapy [OMIT] represents an emerging approach in the management of allergic rhinitis, designed to enhance patient adherence and broaden therapeutic options beyond traditional subcutaneous and sublingual immunotherapy. This session will review the underlying immunologic mechanisms, current clinical evidence, and practical considerations for integrating oral mucosal immunotherapy into clinical practice. Participants will gain insight into how this novel route of administration compares with existing therapies and its potential role in shaping the future of allergy care. 1. Describe the immunologic principles and mechanisms of action underlying oral mucosal immunotherapy. 2. Discuss current clinical data and emerging evidence regarding its efficacy and safety in allergic rhinitis. 3. Discuss practical considerations for patient selection, administration, and integration into allergy management.